U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H27N5
Molecular Weight 325.4512
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAPIPRAZOLE

SMILES

CC1=C(C=CC=C1)N2CCN(CCC3=NN=C4CCCCN34)CC2

InChI

InChIKey=RFWZESUMWJKKRN-UHFFFAOYSA-N
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3

HIDE SMILES / InChI
Molecular Formula C19H27N5
Molecular Weight 325.4512
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Dapiprazole is an alpha-1 adrenergic receptors antagonist which was developed for for the treatment of drug induced mydriasis produced by adrenergic or parasympatholytic agents. The drug was marketed under the name Rev-Eyes, however it was withdrawn from market due to its slow effect.

Approval Year

1990
108

Targets

Primary TargetPharmacologyConditionPotency
Adrenergic receptor alpha-1
169
Antagonist
2,778

Conditions

ConditionModalityTargetsHighest PhaseProduct
Pharmacologically induced mydriasis
2
 Secondary
Approved
8,429
REV-EYES

PubMed

Patents

JP1052722A
2
JP2011528275A
455
JPH00232020A
2
JPH0232020A
2
JPH05194228A
2
JPS6452722A
2

Sample Use Guides

In Vivo Use Guide
The recommended dosage is 2 drops (0.5% solution) followed 5 minutes later by 2 drops.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
5RNZ8GJO7K
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966